ReviewFrontiers in immunology2025
From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Alopecia Areata: Current and Emerging Therapies.Drugs · 2026Review
- Hair Loss Associated With IL-17 and IL-23 Inhibitors: A Systematic Review.International journal of dermatology · 2026Article
- Plant Exosome Injections for Hair Follicle Proliferation and Immune Modulation: An Immunohistochemical Study.Plastic and reconstructive surgery. Global open · 2026Article
- Longitudinal biomarker trajectories accompanying trichoscopic change after PRP-based regimens for alopecia: a complementary multi-marker analysis of a real-world cohort.Journal of medicine and life · 2026Article
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Engineering immune-competent hair follicle microphysiological systems: from organoid assembly to dynamic immune modelling.Frontiers in bioengineering and biotechnology · 2026Review
- IL-15 in alopecia areata: the immune tolerance mechanistic insights and translational perspectives.Frontiers in medicine · 2026Review
- Alopecia areata patients are associated with increased risk of glaucoma: a multicenter, retrospective cohort study.Frontiers in immunology · 2026Article
- Hair loss in the era of CGRP inhibition: emerging evidence, mechanisms, and clinical implications.Frontiers in neurology · 2026Review
- Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance.Frontiers in medicine · 2026Review
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response.Cureus · 2025Article
- Burden of immune-related skin diseases worldwide, 1991-2021: insights and prediction from the Global Burden of Disease Study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is a prevalent autoimmune condition characterized by hair loss, with the collapse of hair follicle immune privilege being a pivotal event in its pathogenesis. This collapse involves intricate immunological disturbances, where CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.